The market for the period 2018-2023 is expected to register a CAGR of
10.5%.

The growth of the market is mainly driven by factors, such as rising
aging population, changes in lifestyle, such as increased intake of
alcohol and disproportionate smoking, and government policies to provide
better care for Kidney Cancer.

Rising Number of Kidney Cancer Cases

The need for early identification of these diseases will lead to the
growth in the market for kidney cancer therapeutics and diagnostics.
Increasing detection of presymptomatic tumors by imaging procedures,
such as ultrasonography, computed tomography, and magnetic resonance
imaging, does not fully explain the upward incidence trends of renal
cell carcinoma.

Other factors, such as increased R&D expenditure of pharmaceutical
companies and increasing incidences of chronic diseases and aging
population will lead to the growth of the market in the forecast period.

Key Highlights

High Cost Associated With Treatment

North America to Dominate Market

Notable Developments

The U.S. Food and Drug Administration today approved Sutent (sunitinib
malate) for the adjuvant treatment of adult patients who are at high
risk of kidney cancer (renal cell carcinoma) returning after a kidney
has been removed (nephrectomy).